Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00804128 · ClinicalTrials.gov registry record

Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)

A clinical trial of Breast Cancer, sponsored by University of California, San Francisco.

Completed
Registry status
76
Enrollment target
1
Study location

NCT00804128 is a study of Breast Cancer that has completed, run by University of California, San Francisco. The registered enrollment target is 76 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00804128, a study of Breast Cancer, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
76 participants
Enrollment target
1
Study location

Study Summary

\*REFERRALS TO THIS TRIAL MUST BE THROUGH BREAST CARE CLINICIANS ONLY\* RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose ductal carcinoma in situ. PURPOSE: This study is to develop and refine magnetic resonance (MR) imaging methods for pre-operative staging of ductal carcinoma in situ, a pre-invasive form of breast cancer, and atypical ductal hyperplasia, a risk factor for developing cancer.

Conditions Studied

Interventions

  • PROCEDURE Magnetic Resonance Imaging (MRI)
  • DRUG Gadavist

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2008-10-01
Est. Completion 2024-01-05

What the Registry Record Tells You About NCT00804128

The ClinicalTrials.gov registry entry for NCT00804128 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.

NCT00804128 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00804128 about?

NCT00804128 is a clinical study titled "Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)". \*REFERRALS TO THIS TRIAL MUST BE THROUGH BREAST CARE CLINICIANS ONLY\* RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose ductal carcinoma in situ. PURPOSE: This study is to develop and refine magnetic resonance (MR) imaging methods for pre-operative stagi...

What is the current status of trial NCT00804128?

This trial is currently completed. The enrollment target is 76 participants. The study started on 2008-10-01. Estimated completion is 2024-01-05.

What conditions does trial NCT00804128 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00804128?

The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Gadavist (DRUG).

Who is sponsoring clinical trial NCT00804128?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00804128 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.